Industry Members
Tissue Regenix, the RegenMed company produces medical devices which uses a proprietary technology platform to make replacement body parts from biological (animal & human) materials. This proprietary platform, known as the dCELL Process, works by removing all cells (decellularisation) from the animal tissue allowing it to be used to replace worn out or diseased body parts.The dCELL process can be used to make 20-30 different products. The three priority markets for the application of the technology are: Vascular; Cardiac; and Orthopaedics. The market for human therapeutic products employing tissue engineering is one of the most rapidly growing sectors within the medical products market, Once regulatory approvals have been obtained, Tissue Regenix will look to license dCELL Technology to third parties and enter co-marketing and/or distribution agreements
Contact: Antony Odell
Address:
The Biocentre
Innovation Way
Heslington
York
YO10 5NY
United Kingdom
Tel: 0870 803 2431
Email:
enquiries@tissueregenix.com
Website:
http://www.tissueregenix.com
